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Abstract
Pancreatic ductal adenocarcinoma induces systemic inflammatory response (SIR), which 
can be assessed either by ratios between blood cell counts (neutrophil to lymphocyte 
ratio, NLR; platelet to lymphocyte ratio, PLR) or concentrations of acute phase proteins, 
clotting factors and albumins. These tests are biologically justified by multiple events 
including bone marrow activation, development of immune-suppressing immature 
myeloid cells, generation of pre-metastatic niches and neutrophil extracellular trap 
formation from externalised DNA network in bidirectional association with platelet 
activation. Despite biological complexity, clinical assessment of SIR is widely available, 
patient-friendly and economically feasible. In this chapter, we present a review on NLR, 
PLR, Glasgow prognostic score and fibrinogen, recently reported to have a prognostic 
role regarding overall survival, cancer/progression free and cancer-specific survival in 
early and advanced pancreatic ductal adenocarcinoma. Practical consequences abound, 
including preference for surgical or combined, active or sparing treatment, as well as 
prediction of non-resectability or chemotherapy response. In this chapter, we also scru-
tinise the main controversies including different cut-off levels, hypothetic correlation 
with tumour burden and morphology, negative findings and discussions on the best 
marker. Future developments should include elaboration of complex scores as will be 
described here.
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1. Introduction
Pancreatic ductal adenocarcinoma (PDAC) is known for notoriously difficult early diagnos-
tics, almost complete lack of well-defined risk groups for targeted surveillance and poor 
response to treatment in advanced stages. Thus, PDAC remains among the most challenging 
cancers for medical professionals today. By incidence, pancreatic cancer was estimated to be 
the 12th most frequent malignant tumour worldwide in the year 2012. However, it ranked 
seventh in the global estimates of oncological mortality for the same year. The dismal prog-
nosis is reflected in the high mortality-to-incidence ratio reaching 0.98 [1]. Pancreatic cancer 
encompasses 2.4% of global cancer incidence and 4.0% of cancer-attributable death cases in 
the world. Even more, it was predicted to be the fourth leading cause of oncological mortality 
in Europe, comprising 6% of cancer-induced death events in 2017 [2]. Considering the grow-
ing incidence, that might be attributable to the epidemic of obesity and metabolic syndrome, 
and low 5-year survival rate (6%), USA research teams have generated prognosis that pan-
creatic cancer might become the second most common cause of oncological mortality by the 
year 2030 [3].
PDAC is responsible for the bulk of pancreatic cancer burden as it is the most common and 
aggressive pancreatic tumour [4]. The overall survival and long-term survival rates of patients 
diagnosed with PDAC generally have not improved in last 30 years, despite multiple inno-
vations in the surgery, including resection of multiple organs; anaesthesia; patient referral 
for surgery in accordance to surgeon’s experience and the excellence of medical team/centre; 
molecular studies and trends towards personalised treatment as well as appearance of new 
drugs [3–5].
Currently, pTNM is the mainstay for pancreatic cancer staging [4]. Molecular portrait is 
important to select targets for personalised treatment. It can have a prognostic role as well. 
However, the current situation forces to look for additional prognostic factors in PDAC, aim-
ing to stratify patient groups by the predicted treatment response or to adjust the necessary 
treatment intensity in order to improve the survival or life quality.
Recently, systemic inflammatory response (SIR) has been highlighted in different cancers, 
including PDAC [6–8]. The network of SIR involves cancer microenvironment, bone marrow 
and metastatic sites, manifesting as the changes of blood cell counts and ratios as well as blood 
levels of acute phase proteins. SIR encompasses complex interactions between at least three 
players: the tumour, the innate and adaptive immunity of the host and the distant tissues.
In SIR, the altered functions of bone marrow lead to switches in production and release of 
inflammatory cells, including neutrophils. Consequently, blood counts of neutrophils increase 
and immature myeloid derived suppressor cells (MDSC) appear in the peripheral blood.
Neutrophils develop in bone marrow, and 90% of the mature cells remain there until acti-
vating stimulus ensures rapid release in appropriate situations. In cancer-induced SIR, 
neutrophils are ejected from bone marrow in response to colony-stimulating factors that are 
produced by the malignant cells. In addition, neutrophil response is incited by tissue dam-
age caused by cancer invasion and/ or by tumour necrosis due to hypoxia and insufficient 
blood supply in the core of growing mass. The colony-stimulating factors influence also 
the CXCR2/CXCR4 chemokine axis that is responsible for the circulation of neutrophils in 
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accordance to cellular maturity and life cycle: retention of immature myeloid cells in the bone 
marrow, release of mature cells upon necessity and return of ageing neutrophils that must be 
destroyed. Consequently, the neutrophil counts in blood of cancer patients increase, and there 
can be a shift to immature cell release.
In tumour microenvironment, neutrophils can differentiate towards either anti-cancerous N1 
or pro-cancerous N2 phenotype (Table 1). These subtypes are considered to represent the 
end points of the activity spectrum, but any neutrophil can exhibit combined traits of both 
subtypes. Transforming growth factor beta is known as a potent mediator of N2 differentia-
tion [9].
Neutrophils are capable to facilitate the metastatic spread of PDAC. Clusters formed by 
neutrophils and circulating cells of pancreatic ductal adenocarcinoma have been observed in 
peritumoural blood vessels. Further, significant relationship was found between neutrophil-
characterising blood indices (neutrophil to lymphocyte ratio) and distant metastasis after 
curative surgery [11]. These clinical observations are explained by a complex network of 
pathogenetic events. Neutrophils can promote tumour cell proliferation and invasion (see 
Figure 1), as well as enhance angiogenesis and increase vascular permeability. Neutrophils 
also represent the main cell population involved in the formation of pre-metastatic niche 
Class Summary activity Features and mechanisms References
N1 neutrophils Anti-tumour Cytotoxic, capable to kill cancer cells: high levels of 
ROS immunostimulatory:
• high levels of Fas, TNF alpha, CCL3, ICAM1;
• low activity of arginase
• lead to activation of T cells
[9]
N2 neutrophils Pro-tumour Lack significant cytotoxic activity
Imunosuppressive: high activity of arginase
Angiogenic: vascular endothelial growth factor 
(VEGF)
Facilitate invasion: matrix metalloproteinases (MMP) 
8, MMP9
[3, 9]
M1 macrophages Pro-inflammatory Restrict cancer growth




Enhance antigen presentation to T lymphocytes
[3]
[10]
M2 macrophages Anti-inflammatory Promote cancer growth
Immunosuppressive: secret IL-10, arginase, 
transforming growth factor beta
Down-regulate MHC class II
Facilitate angiogenesis
Promote cancer cell migration
[3]
[10]
Table 1. The subtypes of neutrophils and macrophages.
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before malignant cells arrive to the site of metastasis. In the pre-metastatic niches, neutrophils 
and immature bone marrow-derived cells gather in clusters that ensure tumour cell hom-
ing. When circulating tumour cells reach the ‘prepared’ metastatic site, neutrophils anchor 
cancer cells to the endothelium, facilitating trans-endothelial migration and invasion. Indeed, 
malignant cells entrapped in distant organs produce cytokines to attract neutrophils. The clas-
sic inflammation-related adhesion molecules, including integrins, can promote cancer cell 
adhesion [9]. Thus, interleukin-induced expression of ICAM1 has been shown to support the 
extravasation of malignant cells and pathogenesis of the PDAC metastasis [12]. Leukotrienes, 
secreted by neutrophils, further promote tumour cell proliferation and growth of the metas-
tasis [9]. To enhance carcinogenesis, neutrophils act in concert with macrophages, similarly 
to the parallel effects of MDSCs and M2 macrophages. For instance, bone marrow-derived 
macrophages are involved in the generation of premetastatic niches by pancreatic cancer exo-
somes [13].
Within the framework of SIR, neutrophils derive unique structures—neutrophil extracellular 
traps (NETs). NETs represent a mesh of chromatin and nuclear proteins [9]. These structures 
possibly have evolutionary developed as a mechanism of antimicrobial response. In cancer 
patient, NETs can wrap a circulating tumour cell, resulting in either reactive oxygen species 
(ROS)-mediated destruction or facilitated adhesion in a pre-metastatic niche. NETosis evolves 
in different stressful conditions, including pre-eclampsia, major surgery or surgical infec-
tion. Consequently, surgery is not only a mechanical tool to withdraw the tumour from the 
body, but it can also become a major immunologic switch. Prolonged or complicated surgical 
intervention might threaten patient’s life directly but also through SIR-associated pathways. 
Indeed, surgical stress or postsurgical infection is shown to facilitate metastatic spread, and 
NETosis is demonstrated in these conditions [9]. SIR-based molecular events highlight the 
association between infection or surgery-induced inflammation [14, 15] and recurrence or 
metastatic spread of the cancer.
Invasive growth of 
cancer
Detachment of individual 
cells and invasion in blood 
vessels or lymphatics
Migration to the 
secondary site
Neu, Mf, Plt Neu, Mf, Plt Neu, Plt
Pre -metastatic niches
Adhesion and extravasation 
at the secondary site
Escape of anoikis in 
blood/ lymph
Neu, Mf, exosomes, 
MDSC, NETs, Plt
Neu Neu, Plt 
Growth of the metastasis to 
gross size
Neu, Mf
Figure 1. The main pathogenetic events in metastatic dissemination of cancer. Abbreviations: Neu, neutrophils; Mf, 
macrophages; Plt, platelets; MDSC, myeloid derived suppressor cells; NETs, neutrophil extracellular traps.
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Neutrophils along with macrophages and other innate immunity cells are considered to have 
predominantly pro-tumourous activity, contrasting with adaptive immunity (lymphocytes) 
having protective role. However, this assumption is not straightforward—N1 neutrophils 
exhibit contra-cancer activity. Type I interferons can convert neutrophils into anti-tumourous 
fighters with rich armoury: enhanced production of ROS, suppressed ability to form pre-
metastatic niches, upregulated ROS-mediated killing of NET-trapped cancer cells, active 
direct cytotoxicity (via ROS or antibody-dependent cell-mediated cytotoxicity) and improved 
capacity to stimulate adaptive immunity [9].
MDSCs represent heterogeneous population of immature cells (namely, the precursors of granu-
locytes, macrophages, monocytes and dendritic cells) sharing immunosuppressive function and 
myeloid origin. These cells express wide spectrum of enzymes, inflammatory mediators as well 
as reactive oxygen species and/or reactive nitrogen intermediates [3]. MDSCs travel via blood 
from their site of origin in bone marrow to the tumour and to peripheral tissues. In the cancer 
microenvironment, MDSCs along with M2 macrophages (see Table 1) exert immunosuppres-
sive effect [16]. Within the complex immunosuppressive network of events in tumours stroma, 
MDSCs suppress the activity of CD8-positive T lymphocytes; induce T-cell apoptosis by ROS 
and nitric oxide derivatives; promote T-cell anergy via regulatory T lymphocytes; inhibit T cell 
migration via nitration of chemokines and T-cell receptors; block interferon (IFN) gamma path-
way and cleave arginine and cysteine via upregulated arginase. The IFN gamma, arginine and 
cysteine are essential for T lymphocyte activity. In addition to the anti-T cell activities, MDSCs 
block the M1 phenotype of tumour-infiltrating macrophages. Production of pro-inflammatory 
interleukin (IL) 6 by MSDCs promote JAK/STAT mediated pathways stimulating cancer cell 
proliferation, survival and evasion from antigen presentation to dendritic cells [3]. In distant 
tissues, immature myeloid cells participate in the generation of pre-metastatic niches [14, 17].
The activities of neutrophils and MDSC in tumour stroma are carried out in cooperation with 
tumour-infiltrating macrophages. Macrophages are recruited by cancer-produced signal 
molecules, including cytokines and growth factors, as well as by tumour necrosis. In cancer 
microenvironment, macrophages acquire M2 differentiation and can enhance tumour pro-
gression, angiogenesis and metastatic spread [10]. M2 macrophages along with MDSC are 
immune suppressors in the cancer stroma [16]. In distant tissues, macrophages assist in the 
creation of premetastatic niches. As noted, this mechanism has been demonstrated in PDAC: 
bone marrow-derived macrophages are involved in the generation of premetastatic niches by 
pancreatic cancer exosomes [13].
In turn, lymphocytes mostly play a defensive role against cancer in the whole body and in 
tumour microenvironment [10].
The pathogenetic association between PDAC and activated blood clotting is acknowledged for 
centuries, reflected by the historic descriptions of migratory thrombophlebitis, also known as 
Trousseau syndrome. The related clinical events include thromboembolism and nonbacterial 
thrombotic endocarditis in cancer patients, occasionally manifesting as the first sign of malignant 
disease [18]. In peripheral blood, platelet counts increase in response to local cancer invasion 
causing endothelial damage. The platelet response is also generated by the pro-inflammatory 
cytokines (IL-1, IL-3 and IL-6) that are produced by the cancer and promote megakaryocyte 
development [8]. Thrombocytosis has been observed in 15.2% of PDAC patients [19].
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Locally, platelets promote angiogenesis, invasion, production of growth factors and adhe-
sion molecules [8]. Platelets facilitate metastatic spread by creating clusters with circulating 
tumour cells and protecting them from immune surveillance, promoting the development of 
pre-metastatic niches and tumour cell attachment to distant tissues. Along with the metastatic 
spread, platelets are suggested to have a major role in epithelial-mesenchymal transition—
process during which epithelial malignant cells change the phenotype to mesenchymal-like, 
plastic cells with enhanced capability for invasion into connective tissues, blood and lym-
phatic vessels as well as metastatic spread [8].
Considering pathogenetic and prognostic role of the interaction between tumour and host 
inflammatory response, systemic inflammatory response has recently become a hot topic in 
medical research. Several indices are elaborated to evaluate SIR (Table 2). Neutrophil to lym-
phocyte ratio (NLR), platelet to lymphocyte ratio (PLR) and Glasgow prognostic score (GPS) 
represent the best-known examples.
Although almost all immune and inflammatory cells can have dual effects in cancer, neu-
trophils mainly act as tumour promoters while lymphocytes represent the protective innate 
immunity. Thus, NLR represents the balance between pro- and contra-tumourous immune 
and inflammatory processes of the host. Similarly, activation of blood clotting is associated 
with burden of invasive tumour, that damages endothelium like ‘dozen of sharp knives’, and 
platelets also facilitate the further development and spread of the cancer while lymphocytes 
exhibit protective action. Hence, PLR is another measure of equilibrium between pro- and 
contra-tumourous events within SIR. GPS reflects the upregulation of acute phase protein 
(measured by the prototypic C-reactive protein) and degree of catabolism by hypoalbumin-
emia. In addition, combined inflammation-based scores have been proposed, derived from 
combinations of SIR-related factors in order to reach higher prognostic value.
Parameter/score Definition
NLR Ratio between the absolute counts of neutrophils and lymphocytes in the 
peripheral blood
PLR Ratio between the absolute counts of platelets and lymphocytes in the peripheral 
blood
Glasgow prognostic score
0 CRP < 10 mg/L AND albumin ≥35 g/L
1 One high-risk finding: CRP ≥ 10 mg/L OR albumin <35 g/L
2 Both high-risk findings: CRP ≥ 10 mg/L AND albumin <35 g/L
Modified Glasgow prognostic score
0 CRP ≤ 10 mg/L irrespective of albumin level
1 Increased CRP on the background of normal albumin level: CRP > 10 mg/L AND 
albumin ≥35 g/L
2 Increased CRP and hypoalbuminemia: CRP > 10 mg/L AND albumin <35 g/L
Abbreviation: CRP, C-reactive protein.
Table 2. Parameters of systemic inflammatory reaction.
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Considering high mortality and poor treatment results of pancreatic ductal adenocarcinoma 
and the need for prognostic and predictive novelties, this chapter scrutinises the assessment 
of SIR in PDAC, potential practical implementations and restrictions of those parameters.
2. NLR in pancreatic ductal adenocarcinoma
Neutrophil to lymphocyte ratio is calculated as the ratio between the count of neutrophilic 
leukocytes and lymphocytes in peripheral blood, using the values detected in a routine full 
blood count. Hence, the parameter is easily available, especially in carefully examined cancer 
patients, and economically nondemanding. In fact, sufficient awareness and algorithm for 
interpretation are the only prerequisites to obtain an additional piece of information from 
routine blood tests. At present, the association between NLR and different aspects of survival, 
for example, overall, recurrence free or cancer-specific survival, remains one of the best sub-
stantiated aspects in the SIR research in cancer.
2.1. NLR and survival
The prognostic importance of NLR is shown over the whole course of PDAC and is applicable 
to wide treatment spectrum—from surgically resectable early cases to advanced or metastatic 
tumours eligible only for non-surgical treatment. Several research teams have demonstrated 
independent prognostic value of NLR, confirmed by multivariate analysis. In few studies, the 
association with survival is confirmed by univariate but not multivariate analysis. Some of the 
reports are on better scores, for example, Glasgow prognostic score had higher informativity 
in the study performed by Yamada et al. [20].
Although only a minor fraction (around 20%) of pancreatic cancers are amenable to surgery, 
surgical removal of tumour is highly advisable, if feasible because surgery provides the only 
definitive cure [5]. Pre-treatment NLR has been evaluated as a prognostic factor for surgically 
treated PDAC patients, mostly with positive findings. Thus, in a large cohort of 442 patients 
subjected to pancreatic resection for PDAC, high NLR was associated with significantly 
lower median survival. The difference was also biologically important: only 12.6 months in 
those presenting with high NLR (defined in this study by receiver operating characteristics 
(ROC) curve analysis as ≥5) patients versus 25.7 months in patients having low NLR. Cox 
proportional hazards analysis confirmed NLR as an independent prognostic factor, associ-
ated with hazard ratio (HR) 1.66; 95% confidence interval (CI): 1.12–2.46; p = 0.012 [21]. In a 
small group of 46 patients subjected to pancreaticoduodenectomy, high NLR (≥2.5) was asso-
ciated with lower overall survival rate. In addition, it predicted surgical complications worse 
than Clavien-Dindo grade 3 [22]. Among 381 patients treated by curative resection of PDAC, 
high NLR (≥2) was significantly and independently associated with overall survival [23]. The 
prognostic value was especially clear in stage I/II [24]. In 110 surgically treated pancreatic 
cancer patients, high NLR (≥5) was an independent prognostic factor for worse cancer-specific 
survival, as confirmed by p < 0.039 [25].
Standard preoperative assessment of NLR is recommended in cases of borderline resectable pan-
creatic cancer by consensus statement by the International Study Group of Pancreatic Surgery [26].
Systemic Inflammatory Response in Pancreatic Ductal Adenocarcinoma
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In most studies, preoperative NLR has been assessed. However, the patient’s immune status 
after the surgery might be as important. Indeed, postoperative NLR, evaluated 1 month after 
the surgery, was shown to have a prognostic value for overall and recurrence-free survival. 
Comparing the patients with NLR ≥ 3 versus NLR < 3.0, the 1-year survival rate was 42.6 
versus 81.9% and 3-year survival rate: 7.3 versus 33.9% (p < 0.001). Notably, the differences 
were confirmed to be statistically significant despite relatively small study group comprising 
86 patients [27].
However, negative observations have also been reported. In a reliably large study group of 
217 surgically treated PDAC patients, overall survival was significantly associated with age, 
adjuvant treatment, cancer invasion in blood vessels and lymphatics, R1 and pTN while NLR 
was not predictive of OS [28]. Assessing 379 consecutive patients who underwent curative 
resection for pancreatic cancer, no significant differences in overall survival were found in 
patients showing high versus low NLR although another SIR marker, the Glasgow prognostic 
score was confirmed as a significant predictor of survival [20].
A meta-analysis of eight studies including 1519 patients with resectable pancreatic cancer 
has been recently carried out by Mowbray et al. [29]. The pooled data confirm association 
between high NLR and low overall survival: HR = 1.77; 95% CI: 1.45–2.15; p < 0.01 [29]. In a 
systematic review of resectable pancreatic cancer, 10 studies were eligible and 8 had reported 
NLR. Significant association with survival was found in three of them [5].
The prognostic value of NLR has also been investigated in advanced and metastatic PDAC 
cases. In a large cohort of patients (497) diagnosed with locally advanced pancreatic cancer 
and treated by neoadjuvant or definitive chemoradiotherapy, elevated NLR was significantly 
associated with worse 1-year overall survival and 1-year progression free survival rates. In 
this study, the median value was selected as the cut-off threshold. Patients presenting with 
low NLR (<1.89), had 1-year survival rate of 73.2% and 1-year progression free survival rate 
of 43.9%, contrasting with those having high NLR (≥1.89): 60.8% survived at least 1-year and 
31.3% were free of progression at least for 1-year (both p < 0.001) as reported by Lee et al., [30]. 
In advanced pancreatic cancer, high NLR was a significant independent prognostic marker 
for shorter survival. The median survival was 2.6 versus 8.5 months in patients having NLR 
≥ 5 versus NLR < 5 [31]. In 132 patients who underwent chemotherapy for advanced pan-
creatic cancer, high baseline NLR (>2.78, based on ROC) and high value after two cycles of 
chemotherapy were associated with lower overall survival. In addition, even worse prog-
nosis was identified in patients who had both these factors. The overall survival was 15.2 
months in patients who had low baseline NLR and did not experience the increase of NLR 
after two cycles of chemotherapy, but only 3.8 months in those having both undesirable fac-
tors: high NLR and increase during treatment. If only baseline NLR was high, the survival 
was 7.6 months. If only NLR increase was observed, the survival was 6.8 months [32]. High 
NRL retained a prognostic value in elderly (at least 75 years of age) patients who underwent 
chemotherapy for unresectable PDAC [33].
Interesting findings have been reported on NLR in patients who underwent preoperative 
chemoradiotherapy followed by complete surgical resection. Such research design allows 
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morphological evaluation of the response to preoperative treatment. Poor response was 
associated with higher pre-treatment NLR [34]. To predict efficacy of chemotherapy, both 
pre-treatment NLR and its dynamics are considered important. Thus, low baseline NLR and 
low NLR after first-line chemotherapy were associated with higher efficacy of chemotherapy 
[8] in parallel to the abovementioned study [32].
In patients receiving stereotactic radiotherapy for advanced PDAC, high NLR (>5) was associ-
ated with significantly shorter median survival: 6.9 versus 8.5 months; p = 0.0057 [35].
Again, the prognostic role of NLR in advanced pancreatic cancer has not always been con-
firmed. In 122 patients, undergoing chemotherapy for inoperable pancreatic cancer, both high 
and low NLR was associated with the same median survival of 10 months. In the same study, 
the dynamics of NLR still predicted outcomes although the biological difference was tiny: the 
median overall was 10 versus 11 months; p < 0.001. The dynamics was assessed as the ratio of 
pre-treatment NLR versus NLR after first-line chemotherapy. Changes in NLR predicted the 
efficacy of chemotherapy and the outcome [8].
The prognostic value of NLR is retained in metastatic PDAC. In treatment-naïve patients 
diagnosed with metastatic PDAC, NLR was significantly associated with survival, and 
multivariate analysis identified NLR as an independent prognostic factor. In addition, NLR 
also predicted the efficacy of oxaliplatin treatment [36]. In 39 patients with locally advanced 
unresectable and metastatic PDAC treated with gemcitabine and paclitaxel, higher NLR was 
associated with lower overall survival [37]. In similar bur larger study group comprising 261 
patients with inoperable pancreatic cancer (both metastatic and locally advanced cases), high 
NLR (≥5) was an independent prognostic factor for worse cancer specific survival, as con-
firmed by p < 0.001 [25]. High NLR was associated with worse overall survival in the general 
group of PDAC patients, in metastatic cases and in those who had distant metastasis but 
also received chemotherapy [38]. Radiofrequency ablation (combined with systemic chemo-
therapy) for hepatic oligometastatic pancreatic cancer was associated with worse survival 
in patients having elevated NLR (≥2.5). In this clinical situation, NLR was confirmed as an 
independent predictive factor, along with cancer location in pancreatic head and diameter of 
the metastasis [39].
In 306 patients receiving palliative chemotherapy, NLR ≥ 5 was associated with shorter over-
all survival. In addition, multivariate analysis identified the independent predictive value of 
NLR [40]. Similarly, prognostic value of NLR in patients receiving palliative chemotherapy 
was reported by Xue et al., [41]. In patients undergoing gastroenterostomy for advanced pan-
creatic cancer, high NLR (≥4) was associated with shorter survival: 3.4 versus 9.4 months; p 
< 0.001 [42]. Thus, low NLR might be useful to identify those who have higher benefit from 
palliative surgery.
Several meta-analyses have been devoted to NLR in pancreatic cancer. Zhou et al. [43] car-
ried out a meta-analysis of 43 cohort studies containing 8252 patients and concluded that 
high NLR was significantly associated with worse overall survival (hazard ratio (HR) = 1.81; 
95% confidence interval (CI): 1.59–2.05; p < 0.001) and cancer-free survival: HR = 1.66; 95% 
CI:1.17–2.35; p = 0.005 [43]. Similar findings were reported by Cheng et al. [44].
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2.2. NLR and cancer burden
2.2.1. NLR and local tumour features: pT and other traits
If NLR in particular and SIR in general are mostly dictated by the events in cancer stroma, 
NLR should correlate with cancer burden, reflected by pT or cancer size. However, the data 
are controversial. Thus, in a study of 442 patients undergoing surgical treatment for pancre-
atic cancer, there was no association between NLR and tumour size or pT. No correlation was 
found with perineural invasion, involvement of resection margins, and invasion into blood 
or lymphatic vessels [21]. In contrast, high NLR (≥2) was significantly associated with pT and 
grade among 381 patients treated by curative resection [23]. In a recent meta-analysis of 8252 
cases, lower NLR was observed in patients having smaller (p = 0.0007), better differentiated 
(p = 0.003) tumours at earlier (p = 0.02) stage [43].
2.2.2. NLR and regional lymph node involvement: pN
The association between NLR and regional lymph node status also is controversial. While 
some research teams have observed higher NLR values in patients affected by tumour metas-
tases in regional lymph nodes, other studies have not confirmed these findings. NLR was 
associated with lymph node metastasis in the study of 159 surgically treated PDAC patients 
[45]. Similarly, high NLR (≥2) was significantly associated with pN among 381 patients treated 
by curative resection [23]. In contrast, no correlation was found between NLR and cancer 
spread to regional lymph nodes reflected by pN or with invasion into lymphatic vessels by 
Sierzega et al. [21], evaluating 442 surgically treated patients. In Austrian cohort of 110 surgi-
cally treated pancreatic cancer patients, NLR lacked correlation with stage [25].
2.2.3. NLR and presence of distant metastasis: pM
In contrast to the previous aspects of tumour burden, namely, pT, size or pN, there is almost 
general agreement that pM1 is associated with higher NLR.
In patients diagnosed with unresectable pancreatic cancer, high pre-treatment NLR signifi-
cantly correlated with presence of liver metastases [8]. Distant metastases were significantly 
more frequently identified in patients presenting with high NLR (>5): 61.6 versus 30.1%; p < 
0.0001 [38]. In advanced pancreatic cancer (including both metastatic and locally advanced 
cases), high NLR (≥5) correlated with the presence of metastatic disease [25]. The association 
between NLR and presence of distant metastases has also been confirmed by a meta-analysis 
by Yang et al., showing the HR = 1.69; 95% CI: 1.10–2.59; p = 0.016 [46].
2.3. Diagnostic role of NLR in pancreatic tumours
The diagnostics of PDAC is frequently a difficult issue. However, the close association 
between chronic pancreatitis and PDAC significantly limits the applicability of SIR for early 
diagnostics.
Baseline NLR in unresectable pancreatic cancer has been found to be significantly higher 
than in healthy controls: 3.81 versus 1.80; p < 0.001 [8]. Although the biological difference 
in the detected levels is remarkable, the comparison between advanced cancer and healthy 
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persons is not the model to make conclusions on the feasibility of NLR for early diagnostics. 
Currently, NLR has no role in the primary diagnostic algorithms for PDAC. However, it can 
assist to solve specific diagnostic questions.
SIR parameters have been proposed as markers of malignancy in pancreatic cystic neoplasms. 
Thus, in 245 patients with mucinous cystic pancreatic neoplasms, NLR ≥ 1.96 was significantly 
(p < 0.001) associated with invasive carcinoma [47]. In 318 surgically treated patients with 
pancreatic cystic neoplasms, high NLR was significantly associated with malignant tumour 
by univariate analysis. However, PLR was found to be superior by multivariate analysis [48].
Regarding intraductal papillary mucinous neoplasms (IPMNs), a trend to higher median 
NLR was observed in malignant cases: 2.23 versus 2.04 in benign cases. However, because of 
the rarity of IPMNs, only 60 patients were enrolled in the study, and the difference in medians 
did not reach statistical significance, reflected by p = 0.14. By the cut-off at 3.6, the prediction 
of malignant behaviour became significant. Still, the sensitivity was only 40% while the speci-
ficity reached 93%. By multivariate analysis, enhancement in a solid nodule was found to be 
superior in comparison with NLR ≥ 3.6 or height of mural nodule ≥11 mm [49]. Assessing 76 
patients, higher NLR was reported in malignant than in benign IPMNs: 2.51 versus 2.01 [50]. 
In a large group of 272 surgically resected IPMNs, NLR exceeding 4.0 was an independent 
factor (by multivariate analysis), associated with invasive carcinoma. To enhance the predic-
tive value, a nomogram was created incorporating NLR (>4.0) along with cyst size (>3 cm), 
identification of enhanced solid component, dilation of pancreatic duct (>5 mm) and the pres-
ence of jaundice [51]. In PDAC patients, significantly higher NLR has been reported than in 
case of pancreatic neuroendocrine neoplasms or pancreatic IPMNs [52].
2.4. Confounding factors in NLR assessment
Smoking and a wide spectrum of non-oncological diseases are known to influence NLR. In 
patients affected by unresectable pancreatic cancer, smoking history significantly (p = 0.001) 
correlated with higher NLR [8].
3. PLR in pancreatic ductal adenocarcinoma
3.1. PLR and survival
PLR is the second best known cellular parameter characterising SIR. Similarly to NLR, 
most studies have concentrated on the prognostic value of PLR regarding the survival. Two 
meta-analyses have been published recently (2018), and both teams have reached very simi-
lar conclusions on the association between elevated PLR and worse overall survival. In a 
meta-analysis of 17 studies on PLR in pancreatic cancer, the negative prognostic role of high 
PLR was confirmed by hazard ratio for worse overall survival HR = 1.28; 95% CI: 1.17–1.40; 
p < 0.001 and worse progression-free survival HR = 1.27; 95% CI = 1.03–1.57; p = 0.03 [53]. 
In another meta-analysis of 17 studies (including 16 reports on association between PLR 
and overall survival in 3028 patients), high PLR also was found to be associated with worse 
overall survival HR = 1.22; 95% CI: 1.09–1.36; p < 0.001. Interestingly, the prognostic role 
was confirmed in the subgroup of Asians (HR = 1.22; 95% CI: 1.11–1.34; p < 0.001) but not 
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Caucasians characterised by HR = 1.20; 95% CI: 0.90–1.62; p = 0.22 [54]. The same conclu-
sion, pointing to significant role of PLR in Asia-based studies but not in those carried out in 
Europe, was reported earlier by Song et al., [55].
Regarding surgically treated PDAC, prognostic role has been ascribed to PLR. In 131 surgi-
cally treated PDAC patients, PLR was an independent factor predicting overall and cancer 
free survival [56]. In a small group of 46 patients treated with pancreaticoduodenectomy for 
pancreatic cancer, high PLR ≥ 200 was associated with lower overall survival and was the only 
independent prognostic indicator contrasting with NLR [22]. In borderline resectable PDAC, 
high PLR (>225) was an independent factor predicting worse survival. The median survival 
was 10.2 versus 24.7 months in high versus low PLR groups; p = 0.003 [57].
However, these findings have been challenged by a lot of contrary reports. PLR did not pre-
dict survival in 217 patients treated for resectable pancreatic cancer [28]. In even larger cohort 
of 442 pancreatic resections for cancer, there was no association between PLR and survival 
although NLR was an independent predictor of poor prognosis [21]. In 159 surgically treated 
patients, PLR lacked prognostic value in regard to overall survival; p = 0.463 although PLR 
was associated with lymph node metastasis that in turn was independent prognostic factor 
for overall survival [45]. In 379 consecutive patients who underwent curative resection for 
pancreatic cancer, PLR was not associated with survival [20]. In 110 surgically treated pan-
creatic cancer patients, high PLR (≥150) was not associated with cancer-specific survival, as 
confirmed by p < 0.458 [25].
In a recent meta-analysis, published in 2018, the association between PLR and overall sur-
vival was not significant in surgically treated patients (HR = 1.45; 95% CI: 0.84–2.50; p = 0.19) 
although it was confirmed in the general group of 3028 patients (HR = 1.22; 95% CI: 1.09–1.36; 
p < 0.001) as well as in subgroups subjected to chemotherapy (HR = 1.18; 95% CI: 1.04–1.35; 
p = 0.01) or combined treatment (HR = 1.29; 95% CI: 1.07–1.57; p = 0.009). The difference 
might be attributable to the patient number, constituting only 228 surgically treated cases 
in contrast to 1313 patients who underwent chemotherapy and 1214—combined treatment 
[54]. However, another meta-analysis including eight studies, 1904 patients and 823 surgically 
treated cases, noted the same lack of association with overall survival shown by HR = 1.24; 
95% CI: 0.95–1.62; p = 0.11 [55].
In 497 patients with locally advanced pancreatic cancer treated by chemoradiotherapy, ele-
vated pre-treatment PLR (defined by the median as ≥149) was associated with worse 1-year 
survival rate and 1-year progression-free survival rate: 61.3 and 32.5% in contrast to those 
presenting with low PLR: 68.1% (p = 0.029) and 37.9% (p = 0.027), respectively [30]. Although 
in this study, both NLR and PLR were significantly associated with survival, greater biologi-
cal differences were observed between NLR-defined groups (Table 3).
Gao et al. also noted that NLR is more sensitive than PLR in predicting treatment efficacy in 
unresectable pancreatic cancer [8]. In 88 pancreatic cancer patients treated by combination 
chemotherapy with gemcitabine and erlotinib, neither progression free survival nor overall 
survival was predicted by PLR while NLR had a prognostic role [58]. In 56 patients subjected 
to preoperative chemoradiotherapy and subsequent surgical treatment allowing to evaluate 
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the pathologic response, higher mean PLR was observed in poor versus good response group: 
172.9 versus 147.3; however, the difference did not reach statistical significance. NLR was 
superior in this study [34]. In 261 patients with inoperable pancreatic cancer (including both 
metastatic and locally advanced cases), high PLR (≥150) was not associated with cancer-spe-
cific survival, as confirmed by p < 0.612 [25].
In contrast, in a small cohort of 66 patients diagnosed with advanced pancreatic cancer, only 
PLR (not NLR or other SIR parameters) was associated with survival [59]. In advanced pan-
creatic cancer, high PLR was a significant independent prognostic marker for shorter sur-
vival. The median survival was 4.0 versus 9.1 months in patients having PLR ≥ 200 versus 
PLR < 200 [31].
3.2. PLR and metastatic spread
Several reports indicate an important role of platelet activation in the metastatic cancer spread. 
PLR was significantly associated with lymph node metastasis; p < 0.001 [45]. Anti-platelet 
treatment, for example, by Clopidogrel, can inhibit the development of metastases [60].
3.3. Diagnostic role of PLR in pancreatic tumours
Differential diagnosis between chronic pancreatitis, presenting with tumour-like mass, and 
pancreatic ductal adenocarcinoma, can be difficult. Although inflammation is involved in 
both diseases, thrombocytosis and lymphopenia are more likely to occur in patients harbour-
ing a malignant tumour. Comparing PLR in PDAC and inflammatory masses of pancreatic 
head, difference was revealed: PLR was 91 (interquartile range (IQR): 77.2–106.6) in patients 
diagnosed with pseudo-tumorous inflammation and 161.9 (IQR: 117.5–205.6) in PDAC. By 
ROC analysis, PLR reached area under curve (AUC) value of 88.8%, and the sensitivity and 
specificity were 79.4 and 92.6%, using cut-off at 113.5 [61]. Another study assessed the diag-
nostic value of PLR in the distinction between inflammatory pancreatic mass and PDAC in 
surgically treated patients. The sensitivity and specificity of PLR was comparable to CA 19-9, 
and combination of both improved the predictive value [62].
In mucinous cystic neoplasms, elevated PLR was shown to be significantly associated with 
presence of invasive carcinoma in 245 patients from Shanghai [47] and 318 patients from 
Singapore [48].
SIR parameter 1-Year overall survival rate 1-Year progression free survival rate
High SIR Low SIR p High SIR Low SIR p
NLR 73.2 60.8 <0.001 43.9 31.3 <0.001
PLR 68.1 61.3 0.029 37.9 32.5 0.027
Abbreviations: SIR, systemic inflammatory reaction; NLR, neutrophil to lymphocyte ratio; PLR, platelet to lymphocyte 
ratio.
Table 3. Prognostic estimated by PLR versus NLR in advanced pancreatic cancer [30].
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4. Classic and modified Glasgow prognostic score in pancreatic 
ductal adenocarcinoma
Glasgow prognostic score is based on the evaluation of the prototypic acute phase protein, 
C-reactive protein; and albumin levels in blood serum. CRP is a nonspecific, but sensitive 
marker of systemic inflammatory reaction, produced in response to pro-inflammatory cyto-
kines (IL-1, IL-6, TNF alpha). Hypoalbuminemia is induced by malnutrition, cancer cachexia 
or SIR. GPS represents a summary estimate of two crucial pathogenetic processes: the humoral 
SIR and cancer cachexia therefore it benefits from considerable sensitivity [14].
Two alterations of Glasgow prognostic score are known: the modified GPS and the high sen-
sitivity GPS. In the modified GPS, albumin level influences the score only if CRP is increased. 
High sensitivity GPS differs from the original GPS by lower cut-off level for CRP [14].
Imaoka et al. evaluated the prognostic value of mGPS across all stages of pancreatic cancer. 
After adjustment, both mGPS values 1 and 2 showed prognostic significance reflected in the 
hazard ratios: mGPS of 1 was associated with HR = 1.772; 95% CI: 1.417–2.215, but mGPS of 
2 yielded HR = 2.033; 95% CI: 1.284–3.219. However, the biological significance was remark-
able between mGPC of 0 and elevated values: the median survival was 15.8 months versus 
5.8 versus 4.8 months in those presenting with mGPS 0, 1 or 2, respectively. In this study, 
the prognostic value of mGPS was not demonstrated in patients who had localised tumours 
and underwent surgical resection. Instead, mGPS was important in advanced pancreatic can-
cer [63]. Similarly, in advanced pancreatic cancer, high mGPS was a significant independent 
prognostic marker for shorter survival. The median survival by mGPS (2 versus 1 versus 0) 
was 1.8 months versus 9.6 versus 8.3 months [31]. As will be discussed further, most scientists 
agree on prognostic role of mGPS in advanced pancreatic cancer. The findings in resectable 
cases are more controversial.
Matsumoto et al reported significant prognostic value of mGPS in resectable pancreatic can-
cer. However, the role of mGPS in this study was to predict recurrence. According to their 
findings, mGPS (2 versus 0 or 1) was an independent predictive factor for tumour recurrence 
within 6 months, along with CA 19-9 (at least 300 U/mL) and tumour diameter (at least 30 
mm). To detect survival, the number of these risk factors was significant, as it was associated 
with significantly (p < 0.001) different median survival: 35.5 versus 26.3 versus 15.9 months in 
those having 0, 1 or 2 or the identified factors, respectively [64].
mGPS (of 2) predicted postoperative pneumonia in 46 patients subjected to pancreaticoduo-
denectomy for pancreatic cancer. However, mGPS was not associated with overall survival 
contrasting with NLR and PLR [22].
Still, several researchers and teams have reported on the association between elevated mGPS 
and survival in surgical PDAC patients. In resectable PDAC, longer overall survival is 
observed in patients having mGPS of 0: 27–37 months contrasting with less than 18 months in 
patients with elevated mGPS [65]. In 101 patients treated by pancreatic resection for PDAC, 
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mGPS of 0, 1 and 2 classified the patients in three distinct groups by overall survival: 37.5 
months, 11.5 months and 7.3 months [66].
Elevated classic GPS (0 versus 1 and 2), was not associated with cancer-specific survival in 110 
surgically treated pancreatic cancer patients, as confirmed by p < 0.585 [25].
Despite the controversies, standard preoperative assessment of mGPS is recommended in 
cases of borderline resectable pancreatic cancer by consensus statement by the International 
Study Group of Pancreatic Surgery [26].
In 261 patients with inoperable pancreatic cancer (including both metastatic and locally 
advanced cases), elevated GPS (0 versus 1 and 2) was significantly associated with worse 
cancer-specific survival, as confirmed by p < 0.029. However, by multivariate analysis, GPS 
was not an independent prognostic factor in this cohort [25]. Nevertheless, the next level of 
evidence has been reached: mGPS was an independent prognostic factor in 187 patients with 
inoperable pancreatic cancer [67]. GPS is associated with survival in patients with unresect-
able pancreatic cancer treated with gemcitabine [68]. In 96 patients who underwent chemora-
diotherapy for histologically confirmed, locally advanced PDAC, Glasgow prognostic score 
(of 2) was an independent predictor of worse overall survival and progression free survival 
[69]. In 40 patients undergoing adjuvant chemotherapy by gemcitabine after curative resec-
tion, elevated GPS (defined as 1 or 2 in contrast to 0) was associated both with worse disease-
free survival (p = 0.001) and overall (p = 0.035) survival [70].
mGPS shows specific associations with response to treatment. Comparing the efficacy of JAK/ 
STAT inhibitor ruxolitinib or placebo in combination with capecitabine (in both groups) for 
second-line treatment of metastatic pancreatic cancer, ruxolitinib showed trend to survival 
benefit only in those patients who had elevated mGPS (1 or 2) or CRP. Thus, in patients 
who had mGPS of 1–2, treatment by ruxolitinib resulted in hazard ratio HR = 0.60; 95% CI: 
0.35–1.03; p = 0.063. In contrast, mGPS of 0 was associated with HR = 0.91; 95% CI = 0.46–1.74; 
p = 0.77. The trend reached statistical significance when the groups were compared by 
C-reactive protein level. Thus, the HR for overall survival in ruxolitinib group was HR = 0.47; 
95% CI: 0.26–0.85; p = 0.011 in patients whose CRP was above the median value (>13 mg/L) 
contrasting with HR = 0.89; 95% CI: 0.47–1.65; p = 0.70 in those who had CRP ≤ 13 mg/L. The 
biological differences were minor: the median survival was 2.7 months receiving ruxolitinib 
versus 1.8 months in controls. The overall survival rates at 3, 6 and 12 months were 48 versus 
29%; 42 versus 11% and 11 versus 0% in the ruxolitinib versus placebo groups [71]. In con-
trast, high mGPS was associated with poor outcome in patients with gemcitabine-refractory 
advanced pancreatic cancer treated by salvage chemotherapy [72].
Modified Glasgow prognostic score was evaluated in 56 patients who underwent preopera-
tive chemoradiotherapy followed by surgical resection of pancreatic cancer, thus ensuring 
the option to assess the treatment efficacy by morphology. By this design, mGPS did not 
predict the response to treatment. However, only five patients presented with mGPS of 1 or 2, 
while most of the cohort (51 cases) had mGPS of 0. All five patients exhibiting elevated mGPS 
responded poorly, but this was insufficient to reach statistical significance [34].
Systemic Inflammatory Response in Pancreatic Ductal Adenocarcinoma
http://dx.doi.org/10.5772/intechopen.78954
17
5. Fibrinogen and D-dimers in pancreatic ductal adenocarcinoma
Extensive alterations of blood clotting have been demonstrated in pancreatic cancer patients. 
Sun et al. characterised different coagulation parameters in 139 patients diagnosed with 
pancreatic cancer and compared the data to forty age- and gender-matched controls. Cancer 
patients had significantly higher level of fibrinogen (p < 0.01), D-dimers (p < 0.01), antithrom-
bin III (p = 0.015), factor VIII (p < 0.01), as well as increased international normalised ratio 
(p = 0.022), longer prothrombin time (p < 0.01) and prolonged activated partial thromboplastin 
time; p < 0.01 [73].
Plasma fibrinogen levels are significantly higher in pancreatic cancer than in case of benign 
pancreatic tumours [74]. Hyperfibrinogenemia has been observed in 24.8% [19]–41.1% of pan-
creatic cancer patients [74]. In pancreatic cancer patients, levels of fibrinogen and D-dimers 
are higher before surgery, but significantly lower at the recurrence-free period after surgery; 
p < 0.01 [75]. Fibrinogen level in pancreatic cancer also correlates with NLR and PLR and 
shows negative correlation with lymphocyte to monocyte ratio [76]. Thus, in pancreatic 
tumours, hyperfibrinogenemia is associated with malignant course, depends on cancer pres-
ence in the body and correlates with SIR parameters. Therefore, elevated fibrinogen level can 
be considered a component of cancer-induced SIR. It is associated with patient’s prognosis.
In 96 patients who underwent chemoradiotherapy for histologically confirmed, locally 
advanced PDAC, elevated fibrinogen level (≥400 mg/dL) was an independent predictor 
of worse overall and progression free survival [69]. Similarly, in 321 patients with locally 
advanced or metastatic pancreatic adenocarcinoma, high plasma fibrinogen was associated 
with shorter survival. It was confirmed an independent prognostic factor [76]. Wang et al. [19] 
also noted the association between higher levels of fibrinogen and worse prognosis. However, 
controversies remain. For instance, elevated preoperative concentrations of D-dimers but not 
fibrinogen were associated with shorter overall and progression-free survival in the study of 
Cao et al. [77].
In PDAC, plasma fibrinogen levels increase along with higher stage. In 125 PDAC patients, 
higher mean fibrinogen concentration was found in stage III/ IV patients compared to those 
diagnosed at stage I/II. Higher levels of fibrinogen correlated with the presence of distant 
metastasis [19, 74].
D-dimers represent another blood clotting parameter that is widely studied in pancreatic 
cancer, including the prognostic role. Thus, elevated preoperative concentrations of D-dimers 
were associated with shorter overall and progression-free survival [77]. D-dimers also reflect 
tumour burden. Higher D-dimer levels in plasma were associated with higher stage and 
grade [73].
Higher concentration of D-dimers predicts shorter survival and non-resectability [75]. The 
association between non-resectability and elevated D-dimer levels in peripheral blood was 
also confirmed by Durczynski et al. [78] who assessed 64 patients. The concentration of 
D-dimers was higher in those who had metastatic cancer in comparison with patients suf-
fering from locally advanced disease [78]. Thus, if the pancreatic tumour seems resectable 
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by preoperative imaging, high preoperative level of D-dimers might suggest the presence of 
occult liver metastases or unresectability of other cause, and the surgery should be started 
with diagnostic laparoscopy in contrast to laparotomy that might turn out to become explor-
atory laparotomy only.
6. Complex SIR-based scores in pancreatic ductal adenocarcinoma: 
presence and future
Considering the complexity of carcinogenesis and inflammation, any single parameter has 
limitations and shortcomings, reflected in the controversial reports. To improve the efficacy 
of SIR parameters, combinations of those have been tested.
6.1. Combination of baseline and dynamic estimates of NLR
In advanced PDAC, several teams have explored the combination of baseline NLR and 
dynamics upon the influence of chemotherapy [32]. The baseline value is scored as high or 
low in regard to threshold level. The cut-offs in SIR studies frequently are identified by ROC 
analysis or by median value. The dynamics is scored as either increase or decrease in response 
to the treatment; ratio between NLR in a predefined time point during treatment versus 
pre-treatment NLR (ratio < 1 is analogous to decrease) or high versus low value (against the 
threshold) in a predefined time point during treatment. The score is based on the count of 
adverse prognostic factors: high baseline NLR or increase of NLR upon treatment.
6.2. NLR and other SIR parameters
Combined SIR scores have been generated, including NLR and other SIR parameters. The 
results might be assessed by the count of adverse prognostic factors, for example high NLR 
or another parameter that exceeds the cut-off level. Summary score including NLR and PLR 
is the most obvious option that has been already successfully tested in other cancers, for 
example, gastric carcinoma [14]. This approach has been fruitful also in PDAC. In patients 
with locally advanced pancreatic cancer treated by chemoradiotherapy, it was noted that the 
combination of both elevated NLR and PLR is associated with especially low 1-year survival 
rate and 1-year progression-free survival rate [30]. Other combinations have been evaluated 
as well, for example, NLR and blood counts of regulatory T lymphocytes in resectable PDAC 
[79]. Combined index based on hypoalbuminemia and NLR has been advocated to evaluate 
the prognosis of gastric cancer [80]. Analogously, in patients receiving stereotactic radiother-
apy for advanced PDAC, high NLR (>5) and low albumin levels were associated with shorter 
median overall survival [35].
6.3. NLR and cancer burden
Currently, there are only few data suggesting dependence of NLR on the tumour burden. The 
correlations with pT or size have been reported with some authors while corroborated by others. 
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Survival studies frequently indicate the independent prognostic value of SIR. Hypothetically, 
SIR is a characteristic of patient’s fight, and not a tumour trait. If so, higher informative value 
could be obtained through complex scores comprising both NLR and an estimate of tumour 
burden by cancer markers (such as CA 19-9 or CEA), positron emission tomography findings 
or clinical characteristics of the tumour, for example, the presence of distant metastases or 
unresectable tumour. All these approaches have been successfully tested in PDAC.
In metastatic pancreatic cancer, a combined score of pre-treatment NLR and CA 19-9 was 
found to be superior to either parameter alone [81]. In resectable pancreatic cancer, the 2-year 
overall survival rate was significantly lower in those presenting with high preoperative NLR 
in combination with high CA 19-9 versus the patients having both values in the low range: 
37.5 versus 89.9%, respectively [82]. A complex score including NLR along with metabolic 
activity detected by positron emission tomography (PET) has been found informative [83]. 
To predict the overall survival of PDAC patients receiving palliative chemotherapy, NLR ≥ 5 
was incorporated in a complex score, designated the prognostic index. The other parameters 
within the framework of this score were performance status, presence of distant metastases or 
unresectable tumour, as well as high CEA or CA 19-9 [40].
6.4. Fibrinogen-based complex scores
Similarly to NLR, fibrinogen level has been successfully incorporated in complex scores along 
with other SIR parameters, for example, GPS, or tumour burden, reflected by stage and/or 
tumour markers, for example, CA19-9. In cancers of other organs, fibrinogen has also been 
assessed along with D-dimer levels or NLR [14].
In 96 patients who underwent chemoradiotherapy for histologically confirmed, locally 
advanced PDAC, Glasgow prognostic score (of 2) and fibrinogen (≥400 mg/dL) were indepen-
dent predictors of worse overall survival and progression free survival. Complex score based 
on fibrinogen and GPS had prognostic value [69].
In a large cohort of patients (321 cases) with locally advanced or metastatic pancreatic adeno-
carcinoma, high plasma fibrinogen was shown to be an independent prognostic factor. It was 
incorporated in a predictive model along with tumour stage and CA 19-9 level, improving the 
predictive capability [76].
Prognostic model for overall survival was elaborated on the basis of independent prognostic 
factors, identified in 125 PDAC patients by the Cox proportional hazard model. These factors 
comprised plasma fibrinogen, cancer stage and the presence of distant metastasis [19].
6.5. SIR-based complex scores: Future developments in PDAC
Carcinomas of different organs differ markedly by their molecular pathogenesis, prognostic 
factors and involvement of the inflammation in various stages of carcinogenesis. In addition, 
even cancers of the same organ are heterogeneous, adding complexity to any cancer research. 
Nevertheless, the keynotes of SIR-based prognostic scores elaborated in cancers other than 
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PDAC might yield fruitful research data. Hypothetically, simultaneous assessment of NLR 
and platelet count, or NLR along with hyperfibrinogenemia might have prognostic value in 
PDAC, especially, considering the marked tendency to up-regulated blood clotting in pancre-
atic cancer patients. NLR can also be evaluated along with GPS or mGPS, or patient’s somatic, 
metabolic and/or psychological status.
7. Conclusions
In conclusion, pancreatic ductal adenocarcinoma is associated with systemic inflammatory 
reaction. The complex pathogenesis of SIR includes ejection of platelets, neutrophils and 
myeloid-derived suppressor cells from bone marrow, development of neutrophil extracel-
lular traps and pre-metastatic niches as well as upregulated levels of acute phase proteins 
and blood clotting factors. Despite the biological complexity, SIR can be easily evaluated by 
patient friendly and cheap blood tests. NLR and PLR are the most frequently used cellular 
SIR parameters reflecting the balance between pro-tumourous (neutrophils, platelets) and 
contra-tumourous (lymphocytes) activities. Glasgow prognostic score, levels of fibrinogen 
and D-dimers characterise proteins that are involved in SIR and thus—in blood clotting. 
Significant associations with survival have been demonstrated, mostly regarding NLR in sur-
gically treated and advanced cases. PLR is beneficial to estimate prognosis in advanced cases. 
Both NLR and PLR can improve the preoperative diagnostics of malignancy in pancreatic 
cystic tumours, while PLR can be helpful to distinguish between pseudo-tumorous chronic 
pancreatitis and PDAC. Complex SIR-based scores are developing in order to increase the 
diagnostic accuracy.
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